BioSpace News Archive

Keros Therapeutics, Inc. (“Keros” or the “Company”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel treatments for patients suffering from hematological and musculoskeletal disorders with high unmet medical need, today provided a business update and reported financial results for the fourth quarter and full year ended December 31, 2021.

Intellia Therapeutics, Inc. announced that the U.S. Food and Drug Administration has granted orphan drug designation for Intellia’s ex vivo investigational T cell receptor -T cell therapy, NTLA-5001, for the treatment of acute myeloid leukemia.

Sientra, Inc. (NASDAQ: SIEN) (“Sientra” or the “Company”), a medical aesthetics company focused on enhancing lives by advancing the art of plastic surgery, today announced that it will release financial results for the fourth quarter and full year of 2021 after the close of trading on Wednesday, March 23, 2022.

Zentalis Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical-stage biopharmaceutical company focused on discovering and developing small molecule therapeutics targeting fundamental biological pathways of cancers, today announced that Anthony Sun, MD, Chairman and Chief Executive Officer of Zentalis, will present a corporate presentation at the Oppenheimer Annual Healthcare Conference.

TFF Pharmaceuticals, Inc. (NASDAQ: TFFP), a clinical-stage biopharmaceutical company focused on developing and commercializing innovative drug products based on its patented Thin Film Freezing (TFF) technology platform, today announced that it will release its financial results and business update for the fourth quarter of 2021 on Thursday, March 24, 2022, at the close of the U.S. financial markets.

ViewRay, Inc. announced that it has reached an agreement with Hudson Executive Capital LP to appoint Susan Schnabel to the ViewRay Board of Directors as an independent director, effective as of March 8, 2022.

Pimera Therapeutics, Inc., a clinical-stage biotechnology company focused on developing breakthrough medicines for cancer and other diseases with high unmet medical need, announced today that an oral presentation on PMR-116 will be delivered at the American Association for Cancer Research (AACR) Annual Meeting 2022.

Myomo, Inc., a wearable medical robotics company that offers increased functionality for those suffering from neurological disorders and upper-limb paralysis, announced financial results for the three months and year ended December 31, 2021.

Brooklyn ImmunoTherapeutics, Inc., a biopharmaceutical company focused on exploring the role that cytokine, and gene editing/cell therapy can have in treating patients with cancer, blood disorders, and monogenic diseases, announced that it has closed its previously announced private placement with a leading healthcare investor.

BIOASIS TECHNOLOGIES INC. announced that Dr. Deborah Rathjen, Executive Chair and Chief Executive Officer of Bioasis will attend and present at the Sachs 5th Annual Neuroscience Innovation Forum Digital conference, including participation on a panel about the Latest Developments in AD & Dementia.